Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2008-04-01
2008-04-01
Haddad, Maher M. (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387300, C530S388100, C530S388220
Reexamination Certificate
active
10449566
ABSTRACT:
CD16A binding proteins useful for the reduction of a deleterious immune response are described. In one aspect, humanized anti-CD16A antibodies, optionally lacking effector function, are used for treatment of immune disorders such as idiopathic thrombocytopenic purpura and autoimmune hemolytic anemia.
REFERENCES:
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5116964 (1992-05-01), Capon et al.
patent: 5219728 (1993-06-01), Khayat et al.
patent: 5399493 (1995-03-01), Emerson et al.
patent: 5428130 (1995-06-01), Capon et al.
patent: 5437994 (1995-08-01), Emerson et al.
patent: 5455030 (1995-10-01), Ladner et al.
patent: 5545806 (1996-08-01), Lonberg et al.
patent: 5569825 (1996-10-01), Lonberg et al.
patent: 5624821 (1997-04-01), Winter et al.
patent: 5641863 (1997-06-01), Schreiber et al.
patent: 5834597 (1998-11-01), Tso et al.
patent: 5837821 (1998-11-01), Wu
patent: 5976831 (1999-11-01), Peltz et al.
patent: 5985599 (1999-11-01), McKenzie et al.
patent: 6025158 (2000-02-01), Gonzalez et al.
patent: 6103889 (2000-08-01), Whitlow et al.
patent: 6194551 (2001-02-01), Idusogie et al.
patent: 6207804 (2001-03-01), Huston et al.
patent: 6277375 (2001-08-01), Ward
patent: 6528624 (2003-03-01), Idusogie et al.
patent: 0 753 065 (1997-01-01), None
patent: 0 343 950 (2000-10-01), None
patent: WO 00/42072 (2000-07-01), None
patent: WO 02/061090 (2002-08-01), None
Vaswani et al. Annals of Allergy, Asthma, & Immunology. 1998, 81:105-116, 119 (pp. 117-118 do not exit).
Brummell et al. Biochemistry. 1993. 32;4:1180-1187.
Rudikoff et al., PNAS 1982 vol. 79, pp. 1979-1983.
Amit et al. Science 1986. 233:747-753.
Alegre, M-L et al. (Jun. 1, 1992). “Effect of a Single Amino Acid Mutation on the Activating and Immunosuppressive Properties of a ‘Humanized’ OKT3 Monoclonal Antibody,”J. Immunol. 148(11):3461-3468.
Altschul, S. F. et al. (1990). “Basic Local Alignment Search Tool,”J. Mol. Biol. 215:403-410.
Anonymous (Dec. 20, 2000). “PerCP Mouse Anti-Human Monoclonal Antibody,” PharMingen Technical Data Sheet, CD3/CD16/CD45, 2 pages.
Anonymous (Jun. 6, 2001). “R-Phycoerythrin (R-PE)-Conjugated Mouse Anti-Human Monoclonal Antibody,” BD PharMingen Technical Data Sheet., CD16, one page.
Barbas, III, C. F. et al. (Sep. 1991). “Assembly of Combinatorial Antibody Libraries on Phage Surfaces: The Gene III Site,”PNAS88:7978-7982.
Bedzyk, W. D. et al. (Jan. 25, 1989). “Comparison of Variable Region Primary Structures Within Anti-Fluorescein Idiotype Family,”J. Biol. Chem. 264(3):1565-1569.
Bird, R. E. et al. (Oct. 21, 1988). “Single-Chain Antigen-Binding Proteins,”Science242:423-426.
Boder, E. T. et al. (Sep. 26, 2000). “Directed Evolution of Antibody Fragments with Monovalent Femtomolar Antigen-Binding Affinity,”PNAS. 97(20):10701-10705.
Boder, E. T. et al. (Jun. 1997). “Yeast Surface Display for Screening Combinatorial Polypeptide Libraries,”Nature Biotechnology15:553-557.
Bolland, S. et al. (1999). “Inhibitory Pathways Triggered by ITIM-Containing Receptors,”Adv. In Immunol. 72:149-177.
Bussel, J. et al. (1988). “Infusion of a Monoclonal Anti-FcR III in Patients with Refractory ITP,”Neo-Adjuvant Chemotherapy169:883-887.
Canfield, S. M. et al. (1991). “The Binding Affinity of Human IgG for Its High Affinity Fc Receptor is Determined by Multiple Amino Acids in the CH2 Domain and Is Modulated by Hinge Region,”J. Exp. Med. 173:1483-1491.
Carter, P. et al. (1992). “High LevelEscherichia coliExpression and Production of a Bivalent Humanized Antibody Fragment,”Bio/Technology10:163-167.
Casali, P. et al. (1986). “Human Monoclonals from Antigen-Specific Selection of B Lymphocytes and Transformation by EBV,”Science234:476-552.
Cheung, R. C. et al. (1990). “Epitope-Specific Antibody Response to the Surface Antigen of Duck Hepatitis B Virus in Infected Ducks,”Virology176:546-552.
Chothia, C. et al. (Dec. 1989). “Conformation of Immunoglobulin Hypervariable Regions,”Nature342:877-883.
Clarkson, S. B. et al. (Aug. 1986). “Blockade of Clearance of Immune Complexes by an Anti-Fcγ Receptor Monoclonal Antibody,”J. Exp. Med. 164:474-489.
Clarkson, S. B. et al. (1986). “Treatment of Refractory Immune Thrombocytopenic Purpura with an Anti-Fcγ-Receptor Antibody,”N. Engl. J. Med. 314(19):1236-1239.
Clynes, R. A. et al. (Apr. 2000). “Inhibitory Fc Receptors Modulate In Vivo Cytoxicity Against Tumor Targets,”Nat. Med. 6(4):443-446.
Co, M. S. et al. (Apr. 1991). “Humanized Antibodies for Antiviral Therapy,”PNAS88:2869-2873.
Daugherty, P. S. et al. (1998). “Antibody Affinity Maturation Using Bacterial Surface Display,”Protein Enginee. 11(9):825-832.
Ding, Y.-H. et al. (Apr. 1998). “Two Human T Cell Receptors Bind in a Similar Diagonal Mode to the HLA-A2/Tax Peptide Complex Using Different TCR Amino Acids,”Immunity8:403-411.
Duncan, A. R. et al. (1988). “Localization of the Binding Site for the Human High-Affinity Fc Receptor on IgG,”Nature332:563-564.
Edge, J . C. et al. (1997). “Cell Type-Specific Glycoforms of FcγRIIIIa (CD16): Differential Ligand Binding,”J. Immunol. 159(8):3849-3857.
Fleit, H. B. et al. (May 1982). “Human Neutrophil FcγReceptor Distribution and Structure,”PNAS79:3275-3279.
Foote, J. et al. (1992). “Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops,”J. Mol. Biol. 224:487-499.
Friend, P.J. et al. (1999). “Phase I Study of an Engineered Aglycosylated Humanized CD3 Antibody in Renal Transplant Rejection,”Transplantation68(11):1632-1637.
Hoogenboom, H. R. and Winter, G. (1991). “By-Passing Immunisation Human Antibodies from Synthetic Repertoires of Germline VH Gene Segments Rearranged in Vitro,”J. Mol. Biol. 227:381-388.
Hudson, P. J. et al. (Jan. 2003). “Engineered Antibodies,”Nature Medicine9(1):129-139.
Huse, W. D. et al. (Dec. 1989). “Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda,”Science246:1275-1281.
Jefferis, R. et al. (1995). “Recognition Sites on Human IgG for Fcγ Receptors: the Role of Glycosylation,”Immunology Letters44:111-117.
Jefferis, R. et al. (1997). “Glycosylation of Antibody Molecules: Structural and Functional Significance,”Chem. Immunol. 65:111-128.
Jones, P. T. et al. (1986). “Replacing the Complementarity Determining Regions in a Human Antibody with Those from Mouse,”Nature321:522-525.
Kirkland, T. N. et al. (1986). “Analysis of the Fine Specificity and Cross-Reactivity of Monoclonal Anti-Lipid A Antibodies,”J. Immunol137(11):3614-3619.
Koumemis, I. L. et al. (2000). “Modulating Pharmcokinetics of An Anti-Interleukin-8 F(ab')2by Amine-Specific PEGylation with Preserved Bioactivity,”Int. J. Pharm. 198:83-95.
Krebs, B. et al. (2001). “High-Throughput Generation and Engineering of Recombinant Human Antibodie,”J. Imm. Methods254:67-84.
Lanzavecchia, A. et al. (1987). “The Use of Hybrid Hybridoma Target Human Cytotoxic T Lymphocytes,”Eur. J. Immunol. 17:105-111.
Larrick, J. W. et al. (1991). “Recombinant Antibodies,”Hum Antibodies Hybribomas2:172-189.
Leong, S. R. et al. (2001). “Adapting Pharmacokinetic Properties of a Humanized Anti-Interleukin-8 Antibody for Therapeutic Applications Using Site-Specific Pegylation,”Cytokine16(3):106-119.
Li, M. et al. (Mar. 1996). “Reconstitution of Human FcyRIII Cell Type Specificity in Transgenic Mice,”J. Exp. Med. 183:1259-1263.
Lucas, B. K. et al. (1996). “High-Level Production of Recombinant Proteins in CHO Cells Using A Dicistronic DHFR Intron Expression Vector,”Nucleic Acids Res. 24(9):1774-1779.
Malmqvist, M. et al.
Huang Ling
Johnson Leslie S.
Li Hua
Tuaillon Nadine
Brivanlou Margaret B.
Crowder Chun
Haddad Maher M.
King & Spalding LLP
Macrogenics Inc.
LandOfFree
CD16A binding proteins and use for the treatment of immune... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with CD16A binding proteins and use for the treatment of immune..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CD16A binding proteins and use for the treatment of immune... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3955035